Clinical Research
corporate_fare

Aer Therapeutics Inc.

Address
8 Davis Drive

Sponsor Overview

assignment
1
sponsored trial
science
1
molecule
location_city
13
research centres
public
3
countries
person_search
13
investigators

Specializations

Respiratory Medicine and Pulmonary Disorders

Aer Therapeutics Inc. demonstrates a focused commitment to advancing treatments for respiratory conditions, with particular emphasis on addressing chronic obstructive pulmonary disease (COPD). The sponsor's research portfolio reflects a dedication to developing novel therapeutic approaches for patients suffering from debilitating lung conditions that significantly impact quality of life and respiratory function.

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Function Optimization
  • Respiratory Tract Therapeutics

The company's therapeutic development strategy centers on innovative interventions designed to improve pulmonary outcomes and provide meaningful clinical benefits for individuals with progressive respiratory disorders. This research direction addresses a substantial unmet medical need in the management of chronic lung diseases.

Innovative Drug Delivery Systems

The sponsor is actively engaged in developing advanced inhalation-based delivery platforms for respiratory therapeutics. This focus on specialized delivery mechanisms demonstrates a commitment to optimizing how medications reach the lungs and ensuring maximal therapeutic efficacy while minimizing systemic exposure and potential adverse effects.

  • Pulmonary Drug Delivery Technologies
  • Inhalation Therapy Optimization
  • Targeted Respiratory Administration

By concentrating on aerosol-based therapeutic delivery, Aer Therapeutics Inc. seeks to enhance patient compliance and treatment effectiveness through improved bioavailability and direct targeting of affected pulmonary tissues.

Sponsored Trials

Trial Name Country Status
A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER 01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary DiseaseBulgaria BulgariaPoland PolandSpain SpainNot Recruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 1 total (100% not shared with other sponsors)

This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 13 sites collaborated multiple times

This sponsor has worked with 13 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Respiratory Tract Diseases1 trial
    277 other sponsors

Partnered Research Centres

13 centres
location_city
assignment53
Area Sanitaria De Ferrol
Address
Avenida Residencia S/n, 15405 Ferrol
Learn morearrow_forward
location_city
assignment38
Asclepius Medical Center OOD
Address
Ploshtad Svoboda 1, 2600 Dupnitsa
Learn morearrow_forward
location_city
assignment52
Centrum Medycyny Oddechowej Mroz Sp. j.
Address
Ul. Piasta 9a, 15-044 Bialystok
Learn morearrow_forward
location_city
assignment2
Clinica Respira-Dr. Juanola
Address
c/ d'Argentona, 84, 08302 Mataró
Learn morearrow_forward
location_city
assignment24
Complex Oncological Center - Shumen EOOD
Address
Ulitsa Vasil Aprilov 63, 9705 Shumen
Learn morearrow_forward
location_city
assignment96
Diagnostics And Consultation Center Convex Ltd.
Address
Ulitsa Sinanishko Ezero 11a, 1680 Sofia
Learn morearrow_forward
Page 1 of 3

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Aer Therapeutics Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.